BALAXI PHARMACEUTICALS LIMITED
BALAXI PHARMACEUTICALS LIMITED (BALAXI) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
balaxipharma.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 Cr | 61 Cr | 60 Cr | 66 Cr | 77 Cr | 73 Cr | 76 Cr | 71 Cr | 56 Cr | 73 Cr | 71 Cr | 81 Cr |
| Operating expenses (approx.) | 44 Cr | 47 Cr | 46 Cr | 56 Cr | 67 Cr | 69 Cr | 64 Cr | 67 Cr | 55 Cr | 69 Cr | 71 Cr | 76 Cr |
| EBITDA | 11 Cr | 14 Cr | 13 Cr | 10 Cr | 11 Cr | 4 Cr | 13 Cr | 4 Cr | 1 Cr | 3 Cr | 0.12 Cr | 5 Cr |
| OPM % | 19.7% | 22.5% | 22.5% | 15.4% | 13.7% | 5.4% | 16.5% | 5.9% | 2.1% | 4.3% | 0.2% | 5.8% |
| Other income | 0.28 Cr | -0.13 Cr | -2 Cr | -2 Cr | -4 Cr | 4 Cr | -2 Cr | -2 Cr | 2 Cr | 0.10 Cr | 3 Cr | -0.99 Cr |
| Interest | 0.37 Cr | 0.41 Cr | 0.60 Cr | 0.37 Cr | 0.45 Cr | 1 Cr | 0.73 Cr | 1 Cr | 0.89 Cr | 1 Cr | 0.99 Cr | 0.73 Cr |
| Depreciation | 0.66 Cr | 0.48 Cr | 0.67 Cr | 0.49 Cr | 0.46 Cr | 0.48 Cr | 0.46 Cr | 0.46 Cr | 0.48 Cr | 0.56 Cr | 0.65 Cr | 0.85 Cr |
| Profit before tax | 16 Cr | 14 Cr | 11 Cr | 7 Cr | 6 Cr | 6 Cr | 10 Cr | 0.90 Cr | 1 Cr | 2 Cr | 1 Cr | 2 Cr |
| Tax % | 7.9% | 4.8% | 4.9% | 12.1% | 17.5% | 11.6% | 10.6% | 67.9% | 84.8% | 81.1% | 56.3% | 37.9% |
| Net profit | 14 Cr | 14 Cr | 11 Cr | 6 Cr | 5 Cr | 5 Cr | 9 Cr | 0.29 Cr | 0.21 Cr | 0.30 Cr | 0.61 Cr | 1 Cr |
| EPS (₹) | ₹14.10 | ₹13.29 | ₹10.41 | ₹1.17 | ₹0.84 | ₹0.97 | ₹1.56 | ₹0.05 | ₹0.04 | ₹0.06 | ₹0.11 | ₹0.24 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 46 Cr | 231 Cr | 279 Cr | 336 Cr | 241 Cr | 293 Cr | 270 Cr | Sign in for TTM |
| Operating expenses (approx.) | 40 Cr | 189 Cr | 229 Cr | 280 Cr | 195 Cr | 255 Cr | 262 Cr | Sign in for TTM |
| EBITDA | 6 Cr | 42 Cr | 50 Cr | 57 Cr | 47 Cr | 37 Cr | 9 Cr | Sign in for TTM |
| OPM % | 13.3% | 18.3% | 18.0% | 16.8% | 19.4% | 12.7% | 3.2% | Sign in for TTM |
| Other income | 3 Cr | 2 Cr | 5 Cr | 3 Cr | -3 Cr | -4 Cr | 3 Cr | Sign in for TTM |
| Interest | 0 Cr | 0.01 Cr | 0.14 Cr | 0.50 Cr | 2 Cr | 3 Cr | 4 Cr | Sign in for TTM |
| Depreciation | 0.0075 Cr | 0.30 Cr | 0.51 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr | Sign in for TTM |
| Profit before tax | 9 Cr | 44 Cr | 55 Cr | 57 Cr | 2 Cr | 29 Cr | 5 Cr | Sign in for TTM |
| Tax % | 31.2% | 14.0% | 12.6% | 19.3% | 218.4% | 12.6% | 73.2% | Sign in for TTM |
| Net profit | 6 Cr | 38 Cr | 48 Cr | 46 Cr | -2 Cr | 25 Cr | 1 Cr | Sign in for TTM |
| EPS (₹) | ₹8.12 | ₹38.14 | ₹47.66 | ₹45.81 | ₹-2.32 | ₹4.54 | ₹0.26 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | 1.1% | — | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 11 Cr | 11 Cr | 11 Cr |
| Reserves | 18 Cr | 0 Cr | 103 Cr | 173 Cr | 190 Cr | 221 Cr | 238 Cr |
| Borrowings | — | — | — | 12 Cr | 18 Cr | 52 Cr | 56 Cr |
| Other liabilities | — | — | — | 45 Cr | 39 Cr | 27 Cr | 32 Cr |
| Total liabilities | — | — | — | 240 Cr | 258 Cr | 310 Cr | 337 Cr |
| Fixed assets (net) | — | — | — | 16 Cr | 15 Cr | 14 Cr | 49 Cr |
| CWIP | — | — | — | 3 Cr | 2 Cr | 22 Cr | — |
| Investments | — | — | — | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Loans & advances | — | — | — | 2 Cr | 2 Cr | 3 Cr | 0.43 Cr |
| Inventories | — | — | — | 105 Cr | 82 Cr | 78 Cr | 83 Cr |
| Trade receivables | — | — | — | 53 Cr | 56 Cr | 111 Cr | 136 Cr |
| Cash & bank | — | — | — | 28 Cr | 62 Cr | 39 Cr | 15 Cr |
| Other assets | — | — | — | 32 Cr | 39 Cr | 42 Cr | 53 Cr |
| Total assets | — | — | — | 240 Cr | 258 Cr | 310 Cr | 337 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 34 Cr | 6 Cr | 5 Cr | -35 Cr | -5 Cr |
| Cash from investing | — | — | -28 Cr | -11 Cr | -1 Cr | -22 Cr | -21 Cr |
| Cash from financing | — | — | -0.16 Cr | 26 Cr | 30 Cr | 34 Cr | 0.44 Cr |
| Net cash flow | — | — | 6 Cr | 21 Cr | 34 Cr | 39 Cr | -25 Cr |
| Free cash flow (OCF − Capex) | — | — | 29 Cr | -7 Cr | 3 Cr | -37 Cr | -25 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 32.0% | — | 48.3% | 29.5% | 1.7% | 11.2% | 3.0% |
| ROE % | 22.0% | 105.8% | 0.0% | 0.0% | 0.0% | 10.8% | 0.6% |
| Debtor days | — | — | — | 58 | 84 | 138 | 183 |
| Inventory days | — | — | — | 189 | 233 | 172 | 201 |
| Days payable | — | — | — | 66 | 82 | 36 | 0 |
| Cash conversion cycle | — | — | — | 181 | 235 | 275 | 385 |
| Debt / equity | — | 0.00 | 0.00 | 0.06 | 0.09 | 0.22 | 0.22 |
| Current ratio | — | — | — | 3.64 | 3.88 | 4.45 | 6.14 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | -0.29 | -0.96 | 0.33 | 4.84 |